Edition:
India

Achillion Pharmaceuticals Inc (ACHN.OQ)

ACHN.OQ on NASDAQ Stock Exchange Global Select Market

3.63USD
1:30am IST
Change (% chg)

$-0.02 (-0.55%)
Prev Close
$3.65
Open
$3.67
Day's High
$3.73
Day's Low
$3.60
Volume
140,404
Avg. Vol
461,889
52-wk High
$5.66
52-wk Low
$2.60

Chart for

About

Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the... (more)

Overall

Beta: 1.68
Market Cap(Mil.): $650.99
Shares Outstanding(Mil.): 136.76
Dividend: --
Yield (%): --

Financials

BRIEF-Achillion Announces ACH-4471 Receives Positive Opinion For Orphan Drug Status In EU For The Treatment Of C3 Glomerulopathy

* ACHILLION ANNOUNCES ACH-4471 RECEIVES POSITIVE OPINION FOR ORPHAN DRUG DESIGNATION IN THE EUROPEAN UNION FOR THE TREATMENT OF C3 GLOMERULOPATHY

26 Feb 2018

BRIEF-Achillion Forecasts 2018 Loss Of $0.55-$0.58 Per Share

* ACHILLION ANNOUNCES RESTRUCTURING TO ADVANCE CORPORATE STRATEGY; ANNOUNCES 2017 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS

22 Feb 2018

BRIEF-Achillion Initiates Phase I First-In Study Of ACH-5228

* ACHILLION INITIATES PHASE I FIRST-IN STUDY OF ACH-5228, A NEXT-GENERATION ORAL SMALL MOLECULE INHIBITOR OF COMPLEMENT FACTOR D

20 Dec 2017

BRIEF-Achillion Announces ACH-4471 Granted Orphan Drug Designation For The Treatment Of C3 Glomerulopathy

* ACHILLION ANNOUNCES ACH-4471 GRANTED ORPHAN DRUG DESIGNATION FOR THE TREATMENT OF C3 GLOMERULOPATHY (C3G) AND THE INITIATION OF A PHASE 1 EXTENDED-RELEASE BIOAVAILABILITY STUDY

18 Dec 2017

BRIEF-Achillion announces pricing of secondary offering of common stock

* Achillion announces pricing of secondary offering of common stock

16 Nov 2017

BRIEF-Achillion announces proposed secondary offering of common stock

* Achillion announces proposed secondary offering of common stock

15 Nov 2017

BRIEF-Achillion reports preliminary proof-of-concept with ACH-4471 for the treatment of c3g

* Achillion reports preliminary proof-of-concept with ACH-4471 for the treatment of c3g

15 Nov 2017

BRIEF-Achillion says ACH-4471 granted orphan drug designation by FDA

* Achillion announces ACH-4471 granted orphan drug designation by the FDA and positive opinion for orphan drug designation in the european union for the treatment of paroxysmal nocturnal hemoglobinuria

06 Nov 2017

BRIEF-Achillion Q3 loss per share $0.14

* Achillion reports third quarter 2017 financial results and provides update on clinical programs

02 Nov 2017

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $36.80 +0.17
Johnson & Johnson (JNJ.N) $126.83 +0.17
Novartis AG (NOVN.S) CHF76.04 -0.04
Merck & Co., Inc. (MRK.N) $60.25 +1.42
Roche Holding Ltd. (ROG.S) CHF217.60 +1.95
Roche Holding Ltd. (RO.S) CHF221.40 +1.40
Abbott Laboratories (ABT.N) $58.84 -0.35
AstraZeneca plc (AZN.L) 5,015.00 +39.00
GlaxoSmithKline plc (GSK.L) 1,445.00 +15.00
Bristol-Myers Squibb Co (BMY.N) $50.90 -0.27

Earnings vs. Estimates